吴丽代会长在致辞中表示，人工智能是推动生产方式全面变革的重要力量，与制造业深度融合是提升产 业竞争力、实现高质量发展的战略选择。深圳作为国家创新型城市和制造业高地，正围绕"人工智能先 锋城市"建设目标，以超过2200家人工智能企业、近200项"城市+AI"应用场景为抓手，全力打造人工智 能全域全时应用先锋城市。深圳工业总会也通过设立相关专业委员会，持续推动人工智能与制造业融 合，助力企业实现从"传统制造"到"智能制造"的跨越。 第七届深圳工业大奖成果发布 "深圳工业大奖"是由深圳工业总会联合相关行业协会和机构共同举办，旨在树立工业标杆，大力弘扬工 业精神，营造重视实体经济的社会氛围，充分发挥深圳工业企业在经济高质量发展中重要作用而设立的 专门奖项。与"中国工业大奖"形成对应体系，是深圳工业界的最高荣誉，也是与"香港工业奖"比肩而立 的大湾区工业界的重要奖项。自2012年启动，每两年评选一次，迄今已成功举办六届，产生较大的社会 反响，受到广大企业的关注和好评。 论坛上，第七届"深圳工业大奖"成果发布隆重举行。贝特瑞、雷曼光电（300162）等10家企业获"深圳 工业大奖"—企业奖，康冠科技（001308）董事长 ...

Core Viewpoint - The forum emphasizes the integration of artificial intelligence (AI) with industrial manufacturing as a strategic choice for enhancing industry competitiveness and achieving high-quality development [6][8][12]. Group 1: Forum Overview - The 14th "Global Industrial Development Forum" and the first Shenzhen Enterprise Transformation and Upgrading Conference were held, focusing on AI and industrial transformation [2][6]. - The forum featured 11 keynote speeches and discussions, highlighting the establishment of the Shenzhen Industrial Association's AI and Robotics Development Committee [6][21]. Group 2: Keynote Insights - The importance of deepening AI applications in core industrial processes was stressed, including enhancing digital design and intelligent control in manufacturing [12]. - A comprehensive analysis of Shenzhen's industrial growth dynamics was presented, identifying five growth drivers and proposing seven key policy recommendations for the AI era [14]. Group 3: Awards and Recognition - The 7th "Shenzhen Industrial Award" was announced, recognizing outstanding enterprises and projects in the industrial sector, with significant contributions from companies like BetterRay and Mindray [10][27]. - The "Shenzhen Enterprise Transformation and Upgrading Research Blue Book" was released, summarizing successful transformation practices and emphasizing innovation-driven strategies [16]. Group 4: AI Applications and Innovations - AI's role in enhancing organizational efficiency and business processes was discussed, with examples of its application in various manufacturing scenarios [18][24]. - The establishment of the AI and Robotics Development Committee aims to create a collaborative innovation platform for industry players [21]. Group 5: Future Directions - The forum highlighted the acceleration of AI from technological breakthroughs to large-scale commercialization, positioning it as a core engine for high-quality development in global manufacturing [29].

Summary of Key Points Core Viewpoint - The article discusses various companies and their shareholders' intentions to buy or sell shares, indicating a trend of both increasing and decreasing shareholdings among different firms in the market [1]. Company Actions - 康缘药业's actual controller's concerted action party increased holdings by 80,000 shares [1]. - 好当家's controlling shareholder plans to reduce holdings by no more than 2.7% [1]. - 亨迪药业's shareholders, including 宁康企管, 倍康企管, and 雷小艳, intend to collectively reduce holdings by no more than 2.33% [1]. - 合兴包装's controlling shareholder 新疆兴汇聚 plans to reduce holdings by no more than 1.91% [1]. - 瑞迈特's shareholder 陈蓓 intends to reduce holdings by no more than 1.76% [1]. - 泰祥股份's 众远投资 plans to reduce holdings by no more than 1% [1]. - 香农芯创's 无锡高新区新动能产业发展基金 reduced holdings by 549,200 shares [1]. - 中国联通's structural adjustment fund will reduce holdings by 40,700,300 shares from November 10 to November 12 [1]. - 方正电机's shareholder 张敏 reduced holdings by 1,632,400 shares [1]. - 畅联股份's directors 徐峰 and 陈文晔 plan to reduce holdings by 0.57% and 0.20%, respectively [1]. - 中兰环保's shareholders 王广庆, 曹丽, and 李泉 plan to reduce holdings by 0.0375%, 0.2798%, and 0.0275%, respectively [1]. - 聚胶股份's director 沃金业 plans to reduce holdings by 0.01% [1]. - 浙江众成's executives 黄旭生 and 潘德祥 plan to reduce holdings by 0.0140% [1]. - 东方中科's shareholder 王戈 plans to reduce holdings by 0.51% [1]. - 海南瑞泽's vice president 于清池 plans to reduce holdings by no more than 0.02% [1].

Group 1 - The core transaction on November 12 involved 18,300 shares of Mindray Medical, with a transaction value of 3.2428 million yuan, at a price of 177.20 yuan, representing a discount of 14.89% compared to the closing price of the day [2][3] - Over the past three months, Mindray Medical has recorded a total of 12 block trades, amounting to a cumulative transaction value of 226 million yuan [2] - The closing price of Mindray Medical on the day of the transaction was 208.20 yuan, reflecting a 0.41% increase, with a turnover rate of 0.62% and a total trading volume of 1.572 billion yuan [2] Group 2 - The latest margin financing balance for Mindray Medical is 4.211 billion yuan, with a decrease of 21.3459 million yuan over the past five days, representing a decline of 0.50% [3] - Mindray Medical was established on January 25, 1999, with a registered capital of 12.1244 billion yuan [3]

Core Viewpoint - The Medical Health R Index (480016) closed at 7616.59 points, up 0.5%, with a trading volume of 25.943 billion yuan and a turnover rate of 0.88% on November 12. The index saw 27 stocks rise, led by BeiGene with a 5.62% increase, while 21 stocks fell, with Tigermed leading the decline at 1.68% [1]. Group 1: Index Performance - The Medical Health R Index reported a net inflow of 537 million yuan from main funds, while retail and speculative funds experienced net outflows of 264 million yuan and 273 million yuan, respectively [1]. - The top ten constituent stocks of the index include WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1]. Group 2: Stock Details - BeiGene (688235) had the highest increase at 5.62%, closing at 293.62 yuan with a market capitalization of 452.37 billion yuan [1]. - Hengrui Medicine (600276) saw a 1.70% increase, closing at 62.10 yuan with a market capitalization of 412.17 billion yuan [1]. - WuXi AppTec (603259) experienced a slight decrease of 0.16%, closing at 92.35 yuan with a market capitalization of 275.55 billion yuan [1]. Group 3: Fund Flow Analysis - Hengrui Medicine had a main fund net inflow of 2.74 million yuan, while speculative funds saw a net outflow of 60.98 million yuan [2]. - BeiGene also experienced a main fund net inflow of 1.81 million yuan, with speculative funds facing a net outflow of 172 million yuan [2]. - The overall fund flow indicates a mixed sentiment among investors, with main funds showing some interest while retail and speculative funds are withdrawing [2].

Core Viewpoint - Mindray has submitted its application for listing on the Hong Kong Stock Exchange, revealing that nearly 50% of its revenue comes from overseas, while also highlighting 11 global risks associated with its international operations [3][4]. Group 1: Listing Application and Revenue Breakdown - Mindray submitted its application for H-share listing on November 10, 2025, to the Hong Kong Stock Exchange [4]. - As of H1 2025, overseas revenue accounted for 49.8% of total revenue, with Europe contributing 9.4%, North America 7.9%, and Latin America 8.3% [5][6]. - The company has achieved a gross profit margin exceeding 60% in H1 2025, positioning it among the top global scientific instrument companies [7]. Group 2: Financial Performance - The total revenue for Mindray in 2022 was approximately RMB 30.37 billion, increasing to RMB 34.93 billion in 2023, and projected to reach RMB 36.73 billion in 2024 [8]. - The gross profit for the same periods was RMB 18.88 billion in 2022, RMB 22.42 billion in 2023, and is expected to be RMB 23.18 billion in 2024 [8]. - The net profit for H1 2025 is projected to be RMB 6.25 million, following a net profit of RMB 9.61 billion in 2022 and RMB 11.58 billion in 2023 [8]. Group 3: Global Risks - Mindray faces various risks in its global operations, including unfamiliarity with overseas regulations and compliance requirements [9]. - Political and economic changes in specific countries or regions, such as instability, inflation, and trade barriers, pose additional risks [9]. - The company also faces challenges related to product liability lawsuits and regulatory scrutiny in international markets [9]. Group 4: Implications for the Industry - The 11 identified risks are highly relevant and serve as significant warnings for other domestic instrument manufacturers looking to expand internationally [10].

Core Insights - The IVD industry is currently facing challenges of declining volume and price, which is impacting the growth of the company's IVD product line [1] - The company believes that the current disruptions are guiding the IVD industry towards refined development, leading to a reduction in unnecessary tests and a focus on tests with clear diagnostic value [1] - The company has outlined a detailed plan to seize the opportunity presented by the industry shift, focusing on R&D and marketing strategies [1] R&D Strategy - The company plans to increase investment in R&D for core businesses such as chemiluminescence, biochemistry, and coagulation [1] - A new generation of coagulation workflow, MT-8000C, has been launched, with plans to release new high-speed chemiluminescence and biochemical analyzers by the end of the year [1] - The company aims to introduce at least 15 new projects annually in chemiluminescence over the next three years, with a goal to match the competitiveness of international giants within two years [1] Marketing Strategy - The company has identified approximately 1,800 major hospitals as the core target for high-end IVD product breakthroughs [1] - The average market share for the company's chemiluminescence, biochemistry, and coagulation products in the domestic market is around 10%, but only 5% in the identified hospitals [1] - The company aims to double its market share in these hospitals over the next three years, despite short-term volume and price adjustments in the IVD industry [1] Long-term Outlook - The company anticipates that diagnostic and surgical volumes will continue to grow, which will support long-term growth in IVD testing volumes [1] - The comprehensive high-end breakthrough in the IVD business is just beginning, indicating a positive growth trajectory for the company [1]

Group 1 - The core point of the article highlights the trading activity of Mindray Medical, which saw a slight increase in stock price and notable block trading activity [1] - On November 12, Mindray Medical's stock closed at 208.20 yuan, with a trading volume of 18,300 shares in a single block trade, amounting to 3.24 million yuan [1] - The first transaction was executed at a price of 177.20 yuan per share, reflecting a premium rate of -14.89%, indicating a discount on the transaction price [1] Group 2 - Over the past three months, Mindray Medical has recorded a total of 12 block trades, with a cumulative transaction value of 226 million yuan [1] - In the last five trading days, the stock has increased by 1.60%, with a net inflow of 168 million yuan from major funds [1]

Core Insights - The report maintains a neutral rating for the pharmaceutical and biotechnology industry, indicating that while there are pressures on performance, there are also opportunities in specific segments that are experiencing growth [5][30]. Market Performance Review - In the first ten months of 2025, the SW pharmaceutical and biotechnology index increased by 21.10%, outperforming the CSI 300 index by approximately 2.26 percentage points, ranking 12th among all Shenwan primary industries [14][19]. - Most sub-sectors within the industry recorded positive returns, with the medical research outsourcing and chemical preparation sectors leading with increases of 60.54% and 40.80%, respectively. Conversely, the blood products and vaccine sectors saw declines of 7.89% and 1.60% [15][19]. - As of October 31, 2025, the overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 53.97 times, which is 4.06 times higher than the CSI 300 index, indicating an increase in industry valuation [19][20]. Policy Outlook for H1 2026 - The 11th batch of national drug centralized procurement is expected to be fully implemented in the first half of 2026, involving 55 varieties and 272 companies, with a selection rate of 57% [30][31]. - The procurement results show a high match between selected brands and clinical needs, with strong supply capabilities from mainstream companies [30]. Sub-sector Highlights Innovative Drugs - Continuous policy optimization supports the development of innovative drugs, with a comprehensive approach to enhance pricing management, insurance coverage, and investment [38]. - The industry is gradually moving away from homogeneous competition, with a significant increase in the proportion of First-in-Class new drug development, which rose by 23 percentage points to 35% since 2020 [38][39]. - Domestic innovative drugs are gaining international recognition, with outbound licensing transactions reaching $66 billion in the first half of 2025, reflecting a growing global presence [41][44]. Medical Devices - The aging population in China is projected to exceed 400 million by 2035, driving demand for medical services and supporting stable growth in the medical device market [50]. - The global medical device market is expected to grow at a compound annual growth rate (CAGR) of 5.7%, reaching $869.7 billion by 2030 [52]. - China's medical device market is rapidly expanding, with projected revenues of 187.5 billion yuan by 2025, indicating significant growth potential [53]. Aesthetic Medicine - The domestic aesthetic medicine market is expected to steadily increase, supported by various policies aimed at promoting healthy industry development and improving market concentration [39]. Synthetic Biology - The market size for synthetic biology is anticipated to approach $40 billion by 2027, driven by multiple factors including technological advancements and increased investment [39].

Group 1: Non-Metallic Building Materials - The building materials industry shows signs of structural growth that gradually outweigh environmental impacts, with Q3 2025 reports indicating a recovery in revenue and profitability for several companies [2][25] - The cement sector continues to perform well overseas, particularly in Africa, while domestic demand and prices have weakened, suggesting a potential bottoming out in 2024 [4][26] - In the consumer building materials sector, revenue growth disparities among sub-industries are widening, driven by the impacts of real estate and local debt [5][27] Group 2: Biopharmaceuticals - Huadong Medicine's industrial segment maintains steady growth, with Q3 2025 revenue of 37.28 billion yuan, up 14.95% year-on-year, and net profit of 8.94 billion yuan, up 18.43% [7][8] - The medical aesthetics business faces short-term pressure due to economic factors, with a decline in revenue for both domestic and overseas operations [8] - The company is advancing its innovative pipeline, with several clinical trials ongoing for various cancer treatments [9][33] Group 3: Power Equipment and New Energy - Haibo Sichuang, a leader in energy storage, is expected to benefit from high industry demand, with Q3 2025 revenue reaching 3.39 billion yuan, a year-on-year increase of 124.4% [10][11] - The company's profitability has improved significantly, with a gross margin of 18.64% and a net margin of 9.05% in Q3 2025 [11] - The global energy storage market is projected to grow by 40%-50% in 2026, with significant contributions from both domestic and international markets [13] Group 4: Financial Engineering - The report highlights various asset allocation strategies, with the macro-factor-based strategy yielding a return of 4.23% in 2025, outperforming other strategies [14][15] - The performance of domestic asset strategies shows a positive trend, with October returns indicating a stable investment environment [15][16] - The overall economic outlook remains cautious, with manufacturing PMI indicating a contraction, while service sector activity shows slight improvement [16]